SHS Gesellschaft für Beteiligungsmanagement mbH

SHS News Current page: 2

18. July 2022 - SHS News

More than 220 million euros for growth and succession investments in European healthcare companies. SHS launches sixth fund generation and exceeds target volume already in first closing

SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over 220 million euros for its sixth fund at the first closing. Faster than expected, the Tübingen-based healthcare investor has already exceeded its target of 200 million euros at the first closing. The sixth SHS fund generation also aims at majority and minority investments in the […]

Read more
21. April 2022 - SHS News

SHS sells shares in Bochum-based phenox GmbH, a leading manufacturer of instruments and implants for the treatment of stroke

The fast-growing MedTech company phenox specialises in instruments and implants for the neurointerventional therapy of stroke With the growth capital provided by SHS et al., the Bochum-based company has developed from a start-up into a global leader in the field of stroke therapy A successful exit for investors from the third SHS fund generation The […]

Read more
15. February 2022 - SHS News

SHS sells leading enzyme engineering company c-LEcta GmbH to Kerry Group

c-LEcta was able to translate technology leadership into tremendous commercial growth during the holding period of SHS Leipzig-based c-LEcta’s clients include international corporations in the pharmaceutical, chemical and food industries. With the acquisition, Kerry Group intends to further expand the internationalization of the company in the field of enzymes Tübingen / 15.02.2022 The Tübingen-based growth […]

Read more
9. November 2021 - SHS News

PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital

This funding round allocated in tranches will strengthen PathoQuest’s position as a leading NGS-based biosafety CRO for the biopharmaceutical industry. Paris, FRANCE, Tübingen, GERMANY – November 9th, 2021 – PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), today announced the closing of a financing round up to €15M. This funding […]

Read more
28. July 2021 - SHS News

SHS sells its stake in Swiss evitria AG, a world market leader in the production of customised antibodies

Atlas Antibodies acquires evitria Atlas Antibodies has agreed to acquire evitria, a world leader in transient recombinant antibody expression in CHO cells. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression. Since its inception in 2010, evitria has been singularly […]

Read more
Previous1
2
34Next